1. Home
  2. VALN vs RAPP Comparison

VALN vs RAPP Comparison

Compare VALN & RAPP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • VALN
  • RAPP
  • Stock Information
  • Founded
  • VALN 2012
  • RAPP 2022
  • Country
  • VALN France
  • RAPP United States
  • Employees
  • VALN N/A
  • RAPP N/A
  • Industry
  • VALN Biotechnology: Biological Products (No Diagnostic Substances)
  • RAPP
  • Sector
  • VALN Health Care
  • RAPP
  • Exchange
  • VALN Nasdaq
  • RAPP Nasdaq
  • Market Cap
  • VALN 542.5M
  • RAPP 439.4M
  • IPO Year
  • VALN 2021
  • RAPP 2024
  • Fundamental
  • Price
  • VALN $6.59
  • RAPP $13.82
  • Analyst Decision
  • VALN Strong Buy
  • RAPP Strong Buy
  • Analyst Count
  • VALN 3
  • RAPP 2
  • Target Price
  • VALN $15.33
  • RAPP $35.00
  • AVG Volume (30 Days)
  • VALN 14.9K
  • RAPP 153.6K
  • Earning Date
  • VALN 08-12-2025
  • RAPP 08-07-2025
  • Dividend Yield
  • VALN N/A
  • RAPP N/A
  • EPS Growth
  • VALN N/A
  • RAPP N/A
  • EPS
  • VALN N/A
  • RAPP N/A
  • Revenue
  • VALN $201,099,222.00
  • RAPP N/A
  • Revenue This Year
  • VALN $18.74
  • RAPP N/A
  • Revenue Next Year
  • VALN $29.26
  • RAPP N/A
  • P/E Ratio
  • VALN N/A
  • RAPP N/A
  • Revenue Growth
  • VALN 21.64
  • RAPP N/A
  • 52 Week Low
  • VALN $3.62
  • RAPP $6.43
  • 52 Week High
  • VALN $8.66
  • RAPP $29.74
  • Technical
  • Relative Strength Index (RSI)
  • VALN 72.04
  • RAPP N/A
  • Support Level
  • VALN $5.82
  • RAPP N/A
  • Resistance Level
  • VALN $6.19
  • RAPP N/A
  • Average True Range (ATR)
  • VALN 0.31
  • RAPP 0.00
  • MACD
  • VALN 0.11
  • RAPP 0.00
  • Stochastic Oscillator
  • VALN 100.00
  • RAPP 0.00

About VALN Valneva SE

Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates majority of its revenue from product sales.

About RAPP Rapport Therapeutics Inc. Common Stock

Rapport Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovery and development of transformational small-molecule medicines for patients suffering from central nervous system disorders. Its foundational science has elucidated the complexities of neuronal receptor biology and enables the company to map and target certain neuronal receptor complexes. Neuronal receptors are complex assemblies of proteins, comprising receptor principal subunits and their receptor-associated proteins (RAPs), the latter of which play crucial roles in regulating receptor expression and function.

Share on Social Networks: